FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171133933> ?p ?o ?g. }

• W2171133933 endingPage "1301" @default.
• W2171133933 startingPage "1289" @default.
• W2171133933 abstract "The treatment efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors like erlotinib has not met expectations for glioblastoma therapy, even for EGFR-overexpressing tumors. We determined possible mechanisms of therapy resistance using the unique BS153 glioblastoma cell line, which has retained amplification of the egfr gene and expression of EGFR variant (v)III.Functional effects of erlotinib, gefitinib, and cetuximab on BS153 proliferation, migration, and EGFR-dependent signal transduction were systematically compared in vitro. The tumor-initiating capacity of parental and treatment-resistant BS153 was studied in Naval Medical Research Institute/Foxn1(nu) mice. Potential mediators of resistance were knocked down using small interfering (si)RNA.Erlotinib and gefitinib inhibited proliferation and migration of BS153 in a dose-dependent manner, whereas cetuximab had no effect. BS153 developed resistance to erlotinib (BS153(resE)) but not to gefitinib. Resistance was associated with strong upregulation of EGFRvIII and subsequent activation of the phosphatidylinositol-3-OH kinase (PI3K) pathway in BS153(resE) and an increased expression of the regulatory 110-kDa delta subunit of PI3K (p110δ). Knockdown of EGFRvIII in BS153(resE) largely restored sensitivity to erlotinib. Targeting PI3K pharmacologically caused a significant decrease in cell viability, and specifically targeting p110δ by siRNA partially restored erlotinib sensitivity in BS153(resE). In vivo, BS153 formed highly invasive tumors with an unusual growth pattern, displaying numerous satellites distant from the initial injection site. Erlotinib resistance led to delayed onset of tumor growth as well as prolonged overall survival of mice without changing tumor morphology.EGFRvIII can mediate resistance to erlotinib in EGFR-amplified glioblastoma via an increase in PI3Kp110δ. Interfering with PI3Kp110δ can restore sensitivity toward the tyrosine kinase inhibitor." @default.
• W2171133933 created "2016-06-24" @default.
• W2171133933 creator A5000795913 @default.
• W2171133933 creator A5002896795 @default.
• W2171133933 creator A5014940156 @default.
• W2171133933 creator A5017579441 @default.
• W2171133933 creator A5057063160 @default.
• W2171133933 creator A5064697931 @default.
• W2171133933 creator A5071626924 @default.
• W2171133933 creator A5078288046 @default.
• W2171133933 creator A5080293557 @default.
• W2171133933 date "2013-07-21" @default.
• W2171133933 modified "2023-09-25" @default.
• W2171133933 title "Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110 " @default.
• W2171133933 cites W1969731848 @default.
• W2171133933 cites W1970174108 @default.
• W2171133933 cites W1973071934 @default.
• W2171133933 cites W1975306522 @default.
• W2171133933 cites W1978916359 @default.
• W2171133933 cites W1982141282 @default.
• W2171133933 cites W1984147944 @default.
• W2171133933 cites W1987797739 @default.
• W2171133933 cites W1995895703 @default.
• W2171133933 cites W2023977540 @default.
• W2171133933 cites W2025786205 @default.
• W2171133933 cites W2026182412 @default.
• W2171133933 cites W2027623923 @default.
• W2171133933 cites W2034301871 @default.
• W2171133933 cites W2043696829 @default.
• W2171133933 cites W2043732412 @default.
• W2171133933 cites W2043739949 @default.
• W2171133933 cites W2070705072 @default.
• W2171133933 cites W2076363741 @default.
• W2171133933 cites W2080877772 @default.
• W2171133933 cites W2086216067 @default.
• W2171133933 cites W2088966231 @default.
• W2171133933 cites W2092452653 @default.
• W2171133933 cites W2093533475 @default.
• W2171133933 cites W2096287682 @default.
• W2171133933 cites W2098399048 @default.
• W2171133933 cites W2101329867 @default.
• W2171133933 cites W2102626211 @default.
• W2171133933 cites W2104743043 @default.
• W2171133933 cites W2107132417 @default.
• W2171133933 cites W2108688211 @default.
• W2171133933 cites W2117941094 @default.
• W2171133933 cites W2121057526 @default.
• W2171133933 cites W2122515815 @default.
• W2171133933 cites W2125662786 @default.
• W2171133933 cites W2133488997 @default.
• W2171133933 cites W2137930630 @default.
• W2171133933 cites W2139203226 @default.
• W2171133933 cites W2143973765 @default.
• W2171133933 cites W2145362489 @default.
• W2171133933 cites W2147881050 @default.
• W2171133933 cites W2154670277 @default.
• W2171133933 cites W2155045369 @default.
• W2171133933 cites W2160511594 @default.
• W2171133933 cites W2164042520 @default.
• W2171133933 cites W2167313634 @default.
• W2171133933 doi "https://doi.org/10.1093/neuonc/not093" @default.
• W2171133933 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3779041" @default.
• W2171133933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23877316" @default.
• W2171133933 hasPublicationYear "2013" @default.
• W2171133933 type Work @default.
• W2171133933 sameAs 2171133933 @default.
• W2171133933 citedByCount "58" @default.
• W2171133933 countsByYear W21711339332014 @default.
• W2171133933 countsByYear W21711339332015 @default.
• W2171133933 countsByYear W21711339332016 @default.
• W2171133933 countsByYear W21711339332017 @default.
• W2171133933 countsByYear W21711339332018 @default.
• W2171133933 countsByYear W21711339332019 @default.
• W2171133933 countsByYear W21711339332020 @default.
• W2171133933 countsByYear W21711339332021 @default.
• W2171133933 countsByYear W21711339332022 @default.
• W2171133933 countsByYear W21711339332023 @default.
• W2171133933 crossrefType "journal-article" @default.
• W2171133933 hasAuthorship W2171133933A5000795913 @default.
• W2171133933 hasAuthorship W2171133933A5002896795 @default.
• W2171133933 hasAuthorship W2171133933A5014940156 @default.
• W2171133933 hasAuthorship W2171133933A5017579441 @default.
• W2171133933 hasAuthorship W2171133933A5057063160 @default.
• W2171133933 hasAuthorship W2171133933A5064697931 @default.
• W2171133933 hasAuthorship W2171133933A5071626924 @default.
• W2171133933 hasAuthorship W2171133933A5078288046 @default.
• W2171133933 hasAuthorship W2171133933A5080293557 @default.
• W2171133933 hasBestOaLocation W21711339331 @default.
• W2171133933 hasConcept C104317684 @default.
• W2171133933 hasConcept C121608353 @default.
• W2171133933 hasConcept C126322002 @default.
• W2171133933 hasConcept C127561419 @default.
• W2171133933 hasConcept C173396325 @default.
• W2171133933 hasConcept C185592680 @default.
• W2171133933 hasConcept C190232843 @default.
• W2171133933 hasConcept C22615655 @default.
• W2171133933 hasConcept C2777506169 @default.
• W2171133933 hasConcept C2778087573 @default.

• next